Hyper-CVAD Treatment in Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Conditions: official terms
Lymphoma - Lymphoma, Non-Hodgkin
Conditions: Keywords
Adult lymphoblastic lymphoma, Hyper-CVAD, first-line treatment
Study Type
Study Phase
Study Design
Time Perspective: Retrospective
Overall Status
Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.
Detailed Description
We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- age over 18 at diagnosis

- Pathologically proven lymphoblastic lymphoma

Exclusion Criteria:

- proven HIV infection

- pretreatment with other regimens
Ajou Universtiy School of Medicine
Suwon, Kyeonggi, Korea, Republic of
Status: Recruiting
Contact: Geum Sook Jeong, MS - +82-31-219-5990 - geumsook@ajou.ac.kr
Start Date
January 2012
Ajou University School of Medicine
Ajou University School of Medicine
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page